Banner Congress EUSAAT 2013 - Linz 2013 - esnats conference

Programme

Download the abstractbook here (high resolution, 36 mb). Or with a low resolution here (4 mb).

 Sunday, 15.09.2013

09:00-11:00   Set-up of exhibition
11:00   Welcome coffee, tea or soft drinks for the participants are available
11:00   Registration open
13:00-13:15   Welcome Addresses

 Session I - International Activities, Disease Models & Human-on-a-chip
 
Chairs: Mardas Daneshian (DE) & Horst Spielmann (DE)

13:15-13:35   Hajime Kojima, National Institute of Health Sciences, JP-Tokyo
Japanese project “ARCH-Tox” for the future chemicals management policy: research and development of in vitro and in vivo assays for internationally leading hazard assessment and test methods
13:35-13:55   Horst Spielmann, Freie Universität Berlin, DE-Berlin
Peer review panel evaluation of the ROS Photosafety Assay
(click to download the presentation as pdf, 1,64 MB)
 13:55-14:15   Mario Fabri, University of Cologne, DE-Cologne
Vitamin D-dependent antimicrobial pathways in human macrophages
14:15-14:35   Günther Weindl, Freie Universität Berlin, DE-Berlin
Increased cutaneous absorption reflects impaired barrier function of reconstructed skin models mimicking keratinisation disorders
14:35-14:55   Eva-Maria Materne, TU Berlin, DE-Berlin
A multi-organ-chip platform for long-term maintenance and substance testing of human tissue co-culture
(click to download the presentation as pdf, 7,16 MB)
 14:55-15:15   Dmitry Sakharov, Scientific Research Centre Bioclinicum, RU-Moscow
A dynamic multi-organ-chip containing enterocytes and hepatocytes for the absorption of orally administered drugs prediction and substance toxicity testing


sponsor

Logo Across Barriers GmbH

15:15-16:30   Poster session I + coffee break and exhibition
Chairs: Eleonore Haltner-Ukomadu (DE) & Tuula Heinonen (SF)
16:30-17:00   Horst Spielmann, Freie Universität Berlin, DE-Berlin
Willi Halle Memorial Lecture
(click to download the presentation as pdf, 3,38 MB)
 Session II – 3Rs go 3D
 Chairs: Helena Kandarova (SK) & Günter Weindl
17:00-17:30   Ellen Fritsche, Leibniz Research Institute of Environmental Medicine, DE-Düsseldorf
Human Neural Progenitor Cell (hNPC) Aging is mimicked by 3D Cultures in vitro: an ‘Adverse Outcome Pathway’ gains importance at susceptible life stages
(click to download the presentation as pdf, 2,8 MB)
17:30-17:45   Jens Kelm, InSphero AG, CH-Zürich
3-dimensional organotypic in vitro model systems for liver, cardiac and neuro safety assessment
17:45-18:00   Silvia Angeloni, CSEM SA, CH-Neuchâtel
Blood-brain tumor and air-blood tissue barrier: two examples of how BioMEMS can improve the relevance of co-cultured in-vitro models of biological barriers
18:00-18:15   Frederique van Acker, TNO Triskelion, NL-Zeist
Cerium oxide nanoparticles air exposure: a comparison study using a human 3D airway model, A549 and BEAS-2B cell lines
18:15-18:30   Nicky Slawny, 3D Biomatrix, Inc., US-Ann Arbor
3D spheroid cell cultures as models in drug discovery
18:30-18:45   Martha Liley. CSEM SA, CH-Neuchâtel
Towards replacing in vivo tests of dental and orthopedic implants

Banner InSphero AG

19:15-20:45    Annual general assembly of EUSAAT
     

 Monday, 16.09.2013 - special day

  ( = session III of the 18th European Congress on Alternatives to Animal Testing)

 ESNATS CONFERENCE - Preliminary Programme

 "Use of Human Embryonic Stem Cells for Novel Toxicity Testing
 Approaches"

09:00-09:10   Horst Spielmann, President of EUSAAT, Freie Universitaet Berlin, DE-Berlin
Opening address
09:10-09:20   Jürgen Hescheler, Coordinator of ESNATS, University of Cologne, DE-Cologne
Overview of the ESNATS project
09:20-10:00   Marcel Leist, University of Konstanz, DE-Konstanz
The ESNATS hESC-based toxicity test battery
10:00-10:40   Jan Hengstler, IFADO, DE-Dortmund
The ESNATS hESC-based toxicity biomarker identification study
10:40-11:00   Jan Hengstler, IFADO, DE-Dortmund
Hepatocyte in vitro systems to study metabolism: stem cell derived hepatocytes as an alternative to primary hepatocytes
11:00-11:15   Coffee break
11:15-11:30   Joery de Kock, Vrije Universiteit Brussels, BE-Brussels
hSKP-derived hepatocytes for toxicity testing
11:30-11:50   Sieto Bosgra, TNO, NL-Utrecht
In vitro-in vivo extrapolation of prenatal (neuro)toxicity assay data by PBPK modeling
11:50-12:10   Agapios Sachinidis, University of Cologne, DE-Cologne
Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells
12:10-12:30   Karl-Heinz Krause, University of Geneva, CH-Geneva
Pluripotent stem cell-derived engineered neural tissues: what’s new?
12:30-13:45   Lunch and posters
 13:45-14:30   First panel discussion (chair: Thomas Hartung, CAAT, US Baltimore)
How can the ESNATS data be used to define mechanisms of action and/or AOPs
 14:30-15:00   Aldert Piersma, RIVM, NL-Bilthoven
Enhancing the readout of the embryonic stem cell test with molecular approaches
 15:00-15:30   Ellen Fritsche, Leibniz Research Institute for Environmental Medicine, DE-Duesseldorf
Signaling pathways in human neural assays (title to be confirmed)
15:30-16:00   Robert Kavlock, US Environmental Protection Agency, US-Washington
Transforming the Conduct of Toxicology in the US: the Tox21 Program
 16:00-16:30   Coffee break and posters
 16:30-17:00   Thomas Knudsen, US Environmental Protection Agency, US-Research Triangle Park
Predictive models and computational embryology
17:00-17:30   Beatriz Silva-Lima, EPAA stem cell group, BE-Brussels
EPAA calls for a “Stem Cells in Safety Testing” forum
to keep fluent communication
 17:30-18:00   Jos Kleinjans, University of Maastricht, NL-Maastricht
Data infrastructure for chemical safety
 18:00-18:45   Second panel discussion (chair: Michael Schwarz, University of Tuebingen, DE-Tuebingen)
How can the ESNATS assays be applicable in companies/regulatory toxicology and what are necessary future developments
 18:45-20:00   Continued discussion and poster session
20:00   Dinner and social evening (at the congress venue)
ESNATS & EUSAAT welcome you!
     

 Tuesday, 17.09.2013

 Session IV – EU Dir 2010/63 & Ethical & legal Aspects
 
Chairs: Susanna Louhimies (BE) & Ursula Sauer (DE)
09:00-09:30   Susanna Louhimies, The European Commission, BE-Brussels
Directive 2010/63/EU: Overview of the work of Commission Expert Working Groups on an EU Framework for Education and Training and on Project Evaluation
(click to download the presentation as pdf, 1,29 MB)
09:30-10:00   Katharina Kluge, Federal Ministry of Food, Agriculture and Consumer Protection, DE-Bonn
Implementation of Directive 2010/63/EU into German law
10:00-10:15   Ursula G. Sauer, Scientific Consultancy - Animal Welfare, DE-Neubiberg
Ethical review of projects involving non-human primates funded under the European Union’s 7th Research Framework Programme
10:15-10:30   Norbert Alzmann, Messerli Research Institute, AT-Vienna
A catalogue of criteria to objectify the harm-benefit analysis according to Austrian legislation
(click to download the presentation as pdf, 0,44 MB)
10:30-10:45   Marie-Jeanne Schiffelers, Utrecht University School of Governance, NL-Utrecht
Factors influencing regulatory acceptance and use of 3R models & strategies to improve this process: The case of the EOGRTS
10:45-11:00   Mangala Gunatilake, University of Colombo, LK-Colombo
Steps taken to implement 3Rs concept in research using animals in Sri Lanka


sponsor
sbv IMPROVER – Systems Biology Verification

 

11:00-11:40   Coffee break, posters and exhibition
 Session V – Consequences of the 2013 EU Marketing Ban for Cosmetics & NanoTox
 Chairs: Dagmar Jirova (CZ) & Klaus Schröder (AT)  
11:40-11:55   Gamze Ates, Vrije Universiteit Brussel, BE-Brussels
Retrospective analysis of the mutagenicity/genotoxicity data of the cosmetic ingredients present on the Annexes of the Cosmetic EU legislation
11:55-12:10   Helena Kandarova, MatTek In Vitro Life Science Laboratories, SK-Bratislava
Ability of the reconstructed human tissue models to correctly predict phototoxicity and photopotency of topically applied substances and formulations: Review of available data
12:10-12:25   Martin Paparella, Environment Agency Austria, AT-Vienna
Uncertainty of testing methods – What do we (want to) know?
(click to download the presentation as pdf, 0,23 MB)
12:25-12:40   Katy Taylor, BUAV/ECEAE, UK-London
The ADAPT principles for regulatory authorities
(click to download the presentation as pdf, 0,67 MB)
12:40-12:55   Stefanie Schindler, Animalfree Research, CH-Bern
Mind the gap - developing and implementing integrated testing strategies into nanotoxicology
(click to download the presentation as pdf, 0,25 MB)
12:55-13:10   Cornelia Loos, University of Ulm, DE-Ulm
The chick chorioallantoic membrane (CAM) assay as a model for the development of antitumor nanotherapeutics


sponsor

Logo British American Tobacco p.l.c.

 

13:10-14:30  

Lunchtime poster session - poster session II
(business lunch to be served at the congress venue)
Chairs: Helena Kandarova (SK) & Ursula Sauer (DE)

 Session VI - Specific Endpoints of Toxicity - Session I (part I)
 Chairs: Rodger Curren (US) & Robert Landsiedel (DE)
14:30-14:50   Robert Landsiedel, BASF SE, DE-Ludwigshafen
Hurdles during the development and application of alternative methods: a perspective from the chemical industry
 14:50-15:05   Judith Madden, Liverpool John Moores University, UK-Liverpool
Modelling local and systemic toxicity: Incorporation of in silico predictions in the development of adverse outcome pathways
(click to download the presentation as pdf, 0,69 MB)
15:05-15:20   Jan Willem Van der Laan, Medicines Evaluation Board, NL-Utrecht
Pharmacology and Carcinogenicity. Predicitivity as a possibility to reduce the number of carcinogenicity studies
15:20-15:35   Katherina Sewald, Fraunhofer ITEM, DE-Hannover
Pre-validation of the ex vivo model PCLS for the prediction of acute inhalation toxicity
15:35-15:50   Rodger Curren, Institute for In Vitro Sciences Inc. (IIVS), US-Gaithersburg, MD
Further refinement of the Reconstructed Skin Micronucleus Genotoxicity Assay (RSMN)
15:50-16:05   TzuTzuy Ramirez Hernandez, BASF SE, DE-Ludwigshafen
Inter-laboratory validation of the Yeast Estrogen and Yeast Androgen Screens for identification of Endocrine Active Substances

 

Banner Primacyt Cell Culture Technology GmbH

 

16:05-16:45   Coffee break, posters and exhibition
 Session VII - Tox21 (TT21C)  & Specific Endpoints of Toxicity (part II)
 Chairs: Carole Mathis (CH) & Roman Kolar (DE)
16:45-17:00   Robert A Coleman, Safer Medicines Trust, UK-London
Humanizing toxicity testing in the 21st century: Who should be responsible for introduction of human biology-based tests into regulatory process?
(click to download the presentation as pdf, 0,21 MB)
17:00-17:15   Carl Westmoreland, Unilever, UK-Bedford
21st century safety science and non animal approaches at Unilever
(click to download the presentation as pdf, 2,09 MB)
17:15-17:30   Marcel Leist, Univ. of Konstanz, DE-Konstanz
Use of transcriptome profiling in stem cell based test systems for reproductive toxicity
17:30-17:45   Julia Hoeng, Philip Morris International, CH- Neuchâtel
Assessing the effects of repeated cigarette smoke exposure using human organotypic systems reproducing the respiratory tract in vitro
17:45-18:00   Anne Krug, Univ. of Konstanz, DE-Konstanz
Integrating transcriptomics and metabolomics to identify pathways of toxicity of the parkinsonian toxin MPP+
18:30   Departure for the social evening
19:00   Social evening

 

Banner Biomimiq – a division of Aeon Astron Europe B.V.

     

 Wednesday, 18.09.2013

 Session VIII - Implementing Alternatives into Basic Research
 
Chairs:Tzutzuy Ramirez-Hernandez (DE) & Tuula Heinonen (SF)
09:00-09:15   Gerhard Püschel, University of Potsdam, DE-Potsdam
Cell culture-based in vitro method for determining the activity of the botulinum toxin
09:15-09:30   Karin Schütze, CellTool GmbH, DE-Bernried
Novel laser-based identification of cancer cells and monitoring of cell-agent interactions
(click to download the presentation as pdf, 4,27 MB)
09:30-09:45   Theresia Licka, University of Veterinary Medicine, AT-Vienna
Research in perfused limbs successfully replaces induction of laminitis in live horses
09:45-10:00   Günther Weindl, Freie Universität Berlin, DE-Berlin
Phase I biotransformation of testosterone by human skin and reconstructed skin tissues
10:00-10:15   Candida Nastrucci, Tor Vergata University, IT-Rome
The alternatives to animal experiments in basic research and education: Status and possibilities in the EU
10:15-10:30   Johannes Grillari, VIBT – BOKU, AT-Vienna
Immortalized primary-like human cells as novel model systems in nephrotoxicity

sponsor

Logo MatTek In Vitro Life Science Laboratories

 

10:30-11:00   Coffee break, posters and exhibition
 Session IX - Drugs, Vaccines & EU FP7 Projects
 Chairs: Horst Spielmann (DE) & Eleonore Haltner-Ukomadu (DE)
11:00-11:18   Maren Bernau, Livestock Center Oberschleissheim, DE- Oberschleissheim
Magnetic resonance imaging as an alternative method in safety-testing of veterinary vaccines – preliminary results in pigs
11:18-11:36   Otmar Schmid, Comprehensive Pneumology Center & Helmholtz Zentrum München, DE-Neuherberg
New perspectives for realistic and efficient in vitro screening for inhalable drugs
11:36-11:54   Jiu Jia, Department of Clinical Pharmacology, University Medicine, Greifswald, Germany
Use of in vitro cell assays and noninvasive imaging techniques to reduce animal experiments in drug development
(click to download the presentation as pdf, 1,32 MB)
11:54-12:12   Francois Busquet, CAAT EU, BE-Brussels
The CAAT EU policy program in Brussels
(click to download the presentation as pdf, 2,46 MB)
12:12-12:30   Sunniva Förster, University of Konstanz, DE-Konstanz
Development and application of an algorithm to determine statistically-valid non-cytotoxic concentrations from imperfect in vitro cytotoxicity data sets
12:30-12:40   Closing remarks
12:40   End of the 18th European Congress on Alternatives to Animal Testing
     
13:00   Start of the post congress EUSAAT 2013 Training Course